Message

On Tuesday October 24th between 7am and 9am, we will carry out scheduled maintenance of the network. During this period of time, there may be potential outages, and the repository may be unavailable.

Thank you for your attention. We apologise for any inconvenience caused.

FLT3 and JAK2 mutations in acute myeloid leukemia promote interchromosomal homologous recombination and the potential for copy neutral loss of heterozygosity

Gaymes, Terry J., Mohamedali, Azim, Eiliazadeh, Anthony L., Darling, David and Mufti, Ghulam J. (2017) FLT3 and JAK2 mutations in acute myeloid leukemia promote interchromosomal homologous recombination and the potential for copy neutral loss of heterozygosity. Cancer Research, 77(7), pp. 1697-1708. ISSN (print) 0008-5472

Full text available as:
[img] Text
Gaymes-T-38273-AAM.pdf - Accepted Version
Restricted to Repository staff only until 20 January 2018.

Download (305kB)

Abstract

Acquired copy neutral LOH (CN-LOH) is a frequent occurrence in myeloid malignancies and is often associated with resistance to standard therapeutic modalities and poor survival. Here, we show that constitutive signaling driven by mutated FLT3 and JAK2 confers interchromosomal homologous recombination (iHR), a precedent for CN-LOH. Using a targeted recombination assay, we determined significant iHR activity in internal tandem duplication FLT3 (FLT3-ITD) and JAK2V617F-mutated cells. Sister chromatid exchanges, a surrogate measure of iHR, was significantly elevated in primary FLT3-ITD normal karyotype acute myeloid leukemia (NK-AML) compared with wild-type FLT3 NK-AML. HR was harmonized to S phase of the cell cycle to repair broken chromatids and prevent iHR. Increased HR activity in G0 arrested primary FLT3-ITD NK-AML in contrast to wild-type FLT3 NK-AML. Cells expressing mutated FLT3-ITD demonstrated a relative increase in mutation frequency as detected by thymidine kinase (TK) gene mutation assay. Moreover, resistance was associated with CN-LOH at the TK locus. Treatment of FLT3-ITD- and JAK2V617F-mutant cells with the antioxidant N-acetylcysteine diminished reactive oxygen species (ROS), restoring iHR and HR levels. Our findings show that mutated FLT3-ITD and JAK2 augment ROS production and HR, shifting the cellular milieu toward illegitimate recombination events such as iHR and CN-LOH. Therapeutic reduction of ROS may thus prevent leukemic progression and relapse in myeloid malignancies.

Item Type: Article
Research Area: Biological sciences
Cancer studies
Faculty, School or Research Centre: Faculty of Science, Engineering and Computing > School of Life Sciences
Related URLs:
Depositing User: Terry Gaymes
Date Deposited: 13 Jun 2017 09:59
Last Modified: 20 Jun 2017 07:23
URI: http://eprints.kingston.ac.uk/id/eprint/38273

Actions (Repository Editors)

Item Control Page Item Control Page